Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALT-005
- Development stage
- Phase 3
- Lead developer
- Altacor
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
ALT-005 is an investigational antimicrobial agent developed for topical use, specifically as an ophthalmic preparation solution. It is being evaluated for its antimicrobial efficacy, particularly in healthy volunteers under controlled conditions where prior antimicrobial use is restricted. Limited public data is available on its detailed mechanism of action, chemical structure, or specific indications beyond infectious diseases.
- Other names
- ALT005ALT-005ALT 005
02
Targets
RyR (Ryanodine receptor family)
Beyond the preview
Go deeper on ALT-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALT-005.